natgillin/translations-raw huggingface dataset:
astemizol eller terfenadin (bruges almindeligvis til at behandle allergiske symptomer, det er medicin som muligvis kan fås uden recept); cisaprid (bruges til at behandle tilbageløb af maveindhold, nogle gange kaldt sure opstød); pimozid (bruges til at behandle skizofreni); amiodaron; dronedaron; quinidin; lidocain (som injektion) eller bepridil (bruges til at korrigere hjerterytmen); ergotamin; dihydroergotamin; ergonovin; ergometrin og methylergonovin (bruges til at behandle migræne); og alfuzosin (bruges til at behandle forstørret blærehalskirtel (prostata)) quetiapin (bruges til at behandle skizofreni, bipolar lidelse (manio-depressiv sygdom) og moderat til svær depression); lurasidon (bruges til at behandle skizofreni) medicin, der indeholder perikon (Hypericum perforatum, et naturlægemiddel).
carbamazepine, phenobarbital and phenytoin (antiepileptics used to prevent seizures) astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); amiodarone, dronedarone, quinidine, lidocaine (injectable) or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, ergometrine and methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder); lurasidone (used to treat schizophrenia) medicines containing St. John's wort (Hypericum perforatum, a herbal preparation).
Samtidig administration med EVOTAZ forventes at øge dolutegravir plasmakoncentrationerne.
Co-administration with EVOTAZ is expected to increase dolutegravir plasma concentrations.
Interaktionsmekanismen er cobicistats P-gp-hæmning.
The mechanism of interaction is inhibition of P-gp by cobicistat.
Interaktionsmekanismen er atazanavirs UGT1A1-hæmning.
The mechanism of interaction is inhibition of UGT1A1 by atazanavir.
Koncentrationen af atazanavir med eller uden cobicistat forventes at øges hos patienter med moderat eller svær nedsat leverfunktion (se pkt.
Concentrations of atazanavir given with cobicistat are expected to be increased in patients with impaired hepatic function (see sections 4.2 and 4.4).
Koncentrationen af disse lægemidler kan øges ved samtidig administration af EVOTAZ.
Concentrations of these medicinal products may be increased when co-administered with EVOTAZ.
Samtidig administration af bepridil er kontraindiceret (se pkt.
Co-administration with bepridil is contraindicated (see section 4.3).
Efter et fedtrigt måltid faldt Cmax og AUC med henholdsvis 36% og 25% sammenlignet med efter et let måltid.
Cmax and AUCs after a high fat meal decreased 36% and 25% in comparison to a light meal, respectively; however, the 24-hour atazanavir concentration was similar when EVOTAZ was given with a light meal and a high fat meal.
Plasmakoncentrationerne af drospirenon forhøjes efter administration af drospirenon/ethinylestradiol med atazanavir/cobicistat.
Plasma concentrations of drospirenone are increased following administration of drospirenone/ethinyloestradiol with atazanavir/cobicistat.
Telaprevir 750 mg tre gange dagligt (atazanavir/ritonavir 300/100 mg 1 gang dagligt)
Telaprevir 750 mg three times daily (atazanavir/ritonavir 300/100 mg once daily)
Dihydroergotamin Ergometrin Ergotamin Methylergonovin
Dihydroergotamine Ergometrine Ergotamine Methylergonovine
Tabletkerne - mikrokrystallinsk cellulose (E460(i)), croscarmellosenatrium (E468), natriumstivlesesglycolat, crospovidon (E1202), stearinsyre (E570), magnesiumstearat (E470b), hydroxypropylcellulose (E463), silica (E551)
Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551) Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Clarithromycin 500 mg to gange dagligt (atazanavir 400 mg 1 gang dagligt)
ANTIBIOTICS Clarithromycin 500 mg twice daily (atazanavir 400 mg once daily)
Interaktionsmekanismen er etravirins CYP3A4-induktion.
The mechanism of interaction is CYP3A4 induction by etravirine.
Interaktionsmekanismen er atazanavirs, cobicistats og ketoconazols eller itraconazols CYP3A4-hæmning.
The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole.
Rosuvastatin (10 mg enkeltdosis) (atazanavir 300 mg 1 gang dagligt med cobicistat 150 mg 1 gang dagligt)
Rosuvastatin (10 mg single dose) (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Samtidig administration af tenofoviralafenamid og cobicistat forventes at øge plasmakoncentrationerne af tenofoviralafenamid og tenofovir.
Co-administration of tenofovir alafenamide with cobicistat is expected to increase tenofovir alafenamide and tenofovir plasma concentrations.
Plasmakoncentrationerne af digoxin kan øges ved samtidig administration af EVOTAZ.
Plasma concentrations of digoxin may be increased when co-administered with EVOTAZ.
disopyramid, flecainid, mexiletin, propafenon, digoxin, bosentan, amlodipin, felodipin, nicardipin, nifedipin, verapamil, diltiazem, metoprolol og timolol (medicin til at sænke blodtrykket og til at nedsætte eller korrigere hjerterytmen (pulsen)) atorvastatin, pravastatin, fluvastatin, pitavastatin og rosuvastatin (bruges til at sænke kolesterolindholdet i blodet) salmeterol (bruges til at behandle astma) ciclosporin, tacrolimus og sirolimus (medicin, der anvendes til at svække kroppens immunsystem) visse antibiotika (rifabutin, clarithromycin) ketoconazol, itraconazol, voriconazol og fluconazol (svampemidler) metformin (bruges til at behandle type 2-sukkersyge) warfarin, rivaroxaban og dabigatran (blodfortyndende midler, anvendes til at mindske risikoen for blodpropper) irinotecan, dasatinib, nilotinib, vinblastin og vincristin (bruges til at behandle kræft) trazodon (bruges til at behandle depression) perphenazin, risperidon, thioridazin, midazolam (givet som injektion), buspiron, clorazepat, diazepam, estazolam, flurazepam og zolpidem (anvendes til at behandle lidelser i nervesystemet) buprenorphin (anvendes mod smerter og til at behandle opioidafhængighed)
It is especially important to mention these: medicines containing ritonavir or cobicistat (booster agents) other medicines to treat HIV infection (e.g. indinavir, didanosine, tenofovir disoproxil, tenofovir alafenamide, efavirenz, etravirine, nevirapine and maraviroc) boceprevir, simeprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil and tadalafil (used by men to treat impotence [erectile dysfunction]) if you are taking an oral contraceptive ("the Pill") any medicines used to treat diseases related to the acid in the stomach (e.g. antacids, H2-blockers like famotidine and proton pump inhibitors like omeprazole) disopyramide, flecainide, mexiletine, propafenone, digoxin, bosentan, amlodipine, felodipine, nicardipine, nifedipine, verapamil, diltiazem, metoprolol and timolol (medicines to lower blood pressure, to slow heart rate or to correct heart rhythm) atorvastatin, pravastatin, fluvastatin, pitavastatin and rosuvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) ciclosporin, tacrolimus and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, voriconazole and fluconazole (antifungals) metformin (used to treat type 2 diabetes) warfarin, rivaroxaban and dabigatran (anticoagulants, used to reduce blood clots) irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer) trazodone (used to treat depression)
EVOTAZ 300 mg/150 mg filmovertrukne tabletter 2.
NAME OF THE MEDICINAL PRODUCT EVOTAZ 300 mg/150 mg film-coated tablets
EVOTAZ tages oralt sammen med føde (se pkt.
EVOTAZ is to be taken orally with food (see section 5.2).
Galdesten er blevet rapporteret hos patienter, der har taget atazanavir (et af indholsstofferne i EVOTAZ).
Gall stones have been reported in patients taking atazanavir, a component of EVOTAZ.
Didanosin (enterokapsler) 400 mg som enkeltdosis (atazanavir 400 mg 1 gang dagligt)
Didanosine (enteric coated capsules) 400 mg single dose (atazanavir 400 mg once daily)
Perikon (Hypericum perforatum) Samtidig brug af perikon og EVOTAZ kan forventes at medføre signifikant fald i atazanavirs og cobicistats plasmaniveauer.
Concomitant use of St. John's wort with EVOTAZ may be expected to result in significant reduction in plasma levels of cobicistat and atazanavir.
Interaktionsmekanismen er atazanavirs og cobicistats P-gp-hæmning.
The mechanism of interaction is P-gp inhibition by atazanavir and cobicistat.
300 mg/pibrentasvir 120 mg 1 gang dagligt (atazanavir 300 mg med ritonavir 100 mg 1 gang dagligt*)
Glecaprevir 300 mg/pibrentasvir 120 mg once daily (atazanavir 300 mg with ritonavir 100 mg once daily*)
Koncentrationer af disse antiarytmika kan øges ved samtidig administration af EVOTAZ.
Concentrations of these antiarrhythmics may be increased when co-administered with EVOTAZ.
Kontraception
Contraception requirements
Colchicin plasmakoncentrationerne kan øges ved samtidig administration af EVOTAZ.
Colchicine plasma concentrations may be increased when co-administered with EVOTAZ.
Samtidig administration af EVOTAZ og disse ergotaminderivater er kontraindiceret (se pkt.
Co-administration of EVOTAZ and these ergot derivates is contraindicated (see section 4.3).
Interaktionsmekanismen er atazanavirs og/eller cobicistats CYP3A4- og/eller CYP2D6-hæmning.
The mechanism of interaction is inhibition of CYP3A4 and/or CYP2D6 by atazanavir and/or cobicistat.
Tenofoviralafenamid 10 mg 1 gang dagligt/emtricitabin 200 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt og cobicistat 150 mg 1 gang dagligt)
Tenofovir alafenamide 10 mg once daily/emtricitabine 200 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Samtidig administration af EVOTAZ og indinavir frarådes (se pkt.
Co-administration of EVOTAZ and indinavir is not recommended (see section 4.4).
Interaktionsmekanismen er nevirapins CYP3A4-induktion og atazanavirs og cobicistats CYP3A4-hæmning.
The mechanism of interaction is CYP3A4 induction by nevirapine and CYP3A4 inhibition by atazanavir and cobicistat.
Samtidig administration af EVOTAZ og alfuzosin er kontraindiceret (se pkt.
Co-administration of EVOTAZ with alfuzosin is contraindicated (see section 4.3)
Lamivudin 150 mg 2 gange dagligt + zidovudin 300 mg 2 gange dagligt (atazanavir 400 mg 1 gang dagligt)
Lamivudine 150 mg twice daily + zidovudine 300 mg twice daily (atazanavir 400 mg once daily)
Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) livstruende uregelmæssige hjerteslag (puls) (torsades de pointes) overfølsomhed (allergisk reaktion) manglende appetit, vægttab, vægtstigning depression, angst, søvnforstyrrelser desorientering, hukommelsestab (amnesi) følelsesløshed, svaghed, prikken eller smerter i arme og ben (perifer neuropati) besvimelse (synkope), højt blodtryk (hypertension) åndenød betændelse i bugspytkirtlen (pankreatitis), irritation af slimhinden i mavesækken (gastritis), sår i munden og forkølelsessår leverbetændelse (hepatitis) angioødem (voldsom hævelse af hud og andre steder, som oftest læber og øjne) nældefeber (kløende udslæt), hårtab eller -udtynding (alopeci), kløe (pruritus) svind af muskelmasse (atrofi), ledsmerter (artralgi), muskelsmerter (myalgi)
Uncommon (may affect up to 1 in 100 people) torsade de pointes (life threatening irregular heart beat) hypersensitivity (allergic reaction) anorexia (loss of appetite), weight loss, weight gain depression, anxiety, sleep disorder disorientation, amnesia (loss of memory) peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores) hepatitis (inflammation of the liver) angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), interstitial nephritis (kidney inflammation), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination), chronic kidney disease (how well your kidneys work) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever asthenia (unusual tiredness or weakness) serious skin rashes (allergic reactions including rash, a high temperature, increased levels of liver enzymes seen in blood tests, an increase in a type of white blood cell [esosinophilia] and/or enlarged lymph nodes) (see section 2) gallbladder disorders (gallstones and gallbladder inflammation)
Knogler, led, muskler og bindevæv ikke almindelig myalgi, muskelatrofi, artralgi sjælden myopati
Adverse Reactions uncommon myalgia, muscle atrophy, arthralgia rare myopathy
Rifabutin 150 mg to gange ugentligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt)
Rifabutin 150 mg twice weekly (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Efavirenz 600 mg 1 gang dagligt (atazanavir 400 mg 1 gang dagligt)
Efavirenz 600 mg once daily (atazanavir 400 mg once daily)
Interaktionsmekanismen er atazanavirs CYP3A4- og UGT1A1hæmning.
The mechanism of interaction is CYP3A4 and UGT1A1 inhibition by atazanavir.
Omeprazol 40 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt, 2 timer efter omeprazol)
Omeprazole 40 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily, 2 hours after omeprazole)
Klinisk monitorering anbefales hvis drospirenon/ethinylestradiol administreres samtidig med atazanavir/cobicistat, grundet potentiel hyperkaliæmi.
If drospirenone/ethinyloestradiol is co-administered with atazanavir/cobicistat clinical monitoring is recommended due to the potential for hyperkalemia.
Interaktionsmekanismen er atazanavirs og cobicistats CYP3Aog/eller P-glycoprotein-hæmning.
The mechanism of interaction is CYP3A and/or P-glycoprotein inhibition by atazanavir and cobicistat.
triazolam og oralt (indtaget gennem munden) midazolam (bruges som sovemedicin og/eller til at behandle angst) simvastatin og lovastatin (bruges til at sænke mængden af kolesterol i blodet) avanil (bruges til at behandle erektil dysfunktion (impotens)).
triazolam and oral (taken by mouth) midazolam (used to help you sleep and/or to relieve anxiety) simvastatin and lovastatin (used to lower blood cholesterol) avanafil (used to treat erectile dysfunction) colchicine (used to treat gout), if you have kidney and/or liver problems ticagrelor (used to reduce the blood clots) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)
Interaktionsmekanismen er CYP3A-hæmning.
The mechanism of interaction is CYP3A inhibition.
Interaktionsmekanismen er rifampicins CYP3A4-induktion.
The mechanism of interaction is CYP3A4 induction by rifampicin.
Omeprazol 20 mg 1 gang dagligt om morgenen (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt om aftenen, 12 timer efter omeprazol)
Omeprazole 20 mg once daily am (atazanavir 300 mg once daily with ritonavir 100 mg once daily pm, 12 hours after omeprazole)
Samtidig administration af følgende lægemidler, som er kraftige induktorer af CYP3A4-isoformen af cytochrom-P450 på grund af den potentielle risiko for tab af terapeutisk virkning (se pkt.
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics) St John's wort (Hypericum perforatum) (herbal product) rifampicin (antimycobacterial)
Interaktionsmekanismen er cobicistats CYP3A4- og P-gp-hæmning.
The mechanism of interaction is CYP3A4 and P-gp inhibition by cobicistat.
Elbasvir 50 mg 1 gang dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt)
Elbasvir 50 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily
Boceprevir 800 mg tre gange dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt)
Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Plasmakoncentrationerne af atorvastatin øges ved samtidig administration med atazanavir/cobicistat
Plasma concentrations of atorvastatin are increased when coadministered with atazanavir/cobicistat
Plasmakoncentrationerne af pitavastatin kan øges ved samtidig administration af EVOTAZ.
Plasma concentrations of pitavastatin may be increased if co-administered with EVOTAZ.
Interaktionsmekanismen er atazanavirs og/eller cobicistats og clarithromycins
The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or cobicistat and clarithromycin.
Rifampicin 600 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt)
Rifampicin 600 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Plasmakoncentrationerne af rosuvastatin øges ved samtidig administration med atazanavir/cobicistat.
Plasma concentrations of rosuvastatin are increased when coadministered with atazanavir/cobicistat.
Nevirapin 200 mg to gange dagligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt)
Nevirapine 200 mg twice daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Der er set unormal hjerterytme (puls) hos patienter, som anvender lægemidler med atazanavir.
There have been reports of unusual heart beat in patients taking atazanavir-containing regimen.
Interaktionsmekanismen er bosentans CYP3A4-induktion.
The mechanism of interaction is induction of CYP3A4 by bosentan.
Tenofoviralafenamid 10 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt og cobicistat 150 mg 1 gang dagligt)
Tenofovir alafenamide 10 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Osteonekrose
ANTIGOUT Colchicine
Koncentrationerne for elbasvir steg betydeligt ved samtidig administration med atazanavir/ritonavir.
Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir
Interaktionsmekanismen er atazanavirs og cobicistats CYP3A-hæmning.
The mechanism of interaction is CYP3A inhibition by atazanavir and cobicistat.
Nevirapin Cmax ↑17% (↑9% ↑25%) Nevirapin Cmin ↑32% (↑22% ↑43%)
Nevirapine Cmin ↑32% (↑22%
Interaktionsmekanismen er cobicistats CYP3A4-hæmning.
The mechanism of interaction is inhibition of CYP3A4 by cobicistat.
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
Do not double the next dose.
Gennemsnitlig halveringstid var, inden for atazanavirs dosisinterval, hos hiv-inficerede voksne patienter (n=33, kombinerede studier) 12 timer ved steady-state efter en dosis på 300 mg dagligt med 100 mg ritonavir én gang dagligt med et let måltid.
12 hours at steady state following a dose of 300 mg daily with ritonavir 100 mg once daily with a light meal.
Nedsat nyrefunktion Atazanavir
Renal impairment Atazanavir
Trazodons plasmakoncentrationer kan øges ved samtidig administration af EVOTAZ.
Plasma concentrations of trazodone may be increased when co-administered with EVOTAZ.
Virkning og anvendelse 2.
What EVOTAZ is and what it is used for 2.
Hvis du har glemt at tage en dosis inden for 12 timer efter det tidspunkt, du normalt tager EVOTAZ, skal du tage tabletten med mad så hurtigt som muligt.
If you miss a dose of EVOTAZ by 12 hours or less, take it right away with food and then take your next scheduled dose at the usual time.
Koncentrationen af betablokkere kan øges ved samtidig administration af EVOTAZ.
Concentrations of beta-blockers may be increased when co-administered with EVOTAZ.
Autoimmune lidelser (såsom Graves sygdom og autoimmun hepatitis) er også rapporteret i forbindelse med immunreaktivering.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Interaktionsmekanismen er atazanavirs og cobicistats CYP3A4-hæmning.
The mechanism of interaction is inhibition of CYP3A4 by atazanavir and cobicistat.
EVOTAZ frarådes til patienter i hæmodialyse (se pkt.
EVOTAZ is not recommended for patients undergoing haemodialysis (see sections 4.4 and 5.2).
4.4 og 4.5 for samtidig adminstration ved behandling af erektil dysfunktion), avanafil (PDE5-hæmmere) simvastatin og lovastatin (HMG-CoA reduktasehæmmere) (se pkt.
Co-administration with the following medicinal products due to the potential for serious and/or lifethreatening adverse reactions (see section 4.5): colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4 and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5) glecaprevir/pibrentasvir fixed dose combination (see section 4.5)
Integrasehæmmere
Integrase Inhibitors
Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide.
If you have any further questions, ask your doctor or pharmacist.
"Essentiel" betyder, at sygdommen ikke har nogen åbenlys årsag.
‘Essential' means that the disease has no obvious cause.
Resultater ses sædvanligvis inden for to til tre uger efter påbegyndt behandling.
Results are normally seen within 2 or 3 weeks of starting treatment.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Anagrelide Mylan.
This is a summary of the European public assessment report (EPAR) for Anagrelide Mylan.
Den fuldstændige EPAR for Anagrelide Mylan findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Anagrelide Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Efter en uge øges dosis hver uge med 0,5 mg dagligt, indtil blodpladetallet er under 600 mio. blodplader pr. ml og ideelt mellem 150 og 400 mio./ml (det antal, der normalt observeres hos sunde personer).
After a week, the dose is increased every week by 0.5 mg a day, until the platelet count is below 600 million platelets per millilitre, and ideally between 150 and 400 million/ml (the level usually seen in healthy people).
Behandling bør kun iværksættes af en læge med erfaring i behandling af essentiel trombocytæmi.
Treatment should only be started by a doctor who has experience in treating essential thrombocythaemia.
Agenturet anbefalede, at Anagrelide Mylan godkendes til anvendelse i EU.
The Agency recommended that Anagrelide Mylan be approved for use in the EU.
Som for alle lægemidler fremlagde virksomheden undersøgelser af kvaliteten af Anagrelide Mylan.
As for every medicine, the company provided studies on the quality of Anagrelide Mylan.
Anagrelide Mylan anvendes, når patientens hidtidige behandling ikke virker godt nok eller medfører uacceptable bivirkninger, og når patienten tilhører "risikogruppen" enten på grund af alder (over 60 år), meget højt blodpladetal eller tidligere størkningsproblemer.
Anagrelide Mylan is used when the patient's current treatment does not work well enough or has unacceptable side effects, and when they are ‘at risk' because of their age (over 60 years), very high platelet counts or previous clotting problems.